About 1 in 8 adults in the United States has used a GLP-1 drug like Ozempic or Mounjaro at some point in their life, and half of them about 6% of adults, or more than 15 million people are currently using a prescription, according to new survey data from KFF
Key Players 1
Despite all the changes, it seems likely that compounding pharmacies will continue to offer GLP-1 drugs, at least for the foreseeable future, says Brunner: Some patients will be able to maintain these therapies at a price point they can afford in a customized formulation. The Takeaway The FDA ordered compounding pharmacies to stop producing and selling copies of GLP-1 injectable drugs like Ozempic, Wegovy, Mounjaro, and Zepbound, as official shortages have ended
Rotate your injection site each week to prevent tissue irritation
The limitation of lipidation: conversion of semaglutide from once-weekly to once-monthly dosing
HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT Methodology This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information to analyze the global GLP-1 agonists market